Johnson, Daniel H.

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersTransplantation: Methods and Outcomes

Cited by 294

Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series

Kim, S. T., Tayar, J., Trinh, V. A., Suarez-Almazor, M., Garcia, S., Hwu, P., Johnson, D. H., Uemura, M., & Diab, A. (2017) · Annals of the Rheumatic Diseases

Cancer Immunotherapy and BiomarkersRheumatoid Arthritis Research and Therapies

Cited by 170

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 111

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.

Johnson, D. H., Hailemichael, Y., Foo, W. C., Hess, K. R., Haymaker, C. L., Wani, K. M., Lazar, A. J., Saberian, C. M., Bentebibel, S. E., Burton, E. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 9